Roche pulls out of 'superbug' antibiotic project

VIENNA Swiss drugmaker Roche Holding has dropped out of a high-profile project to develop an antibiotic for treating “superbug” infections, the company said on Sunday.

Roche had agreed in 2013 to pay privately held partner Polyphor up to 500 million Swiss francs ($485.3 million) for rights to the product, marking a rare foray by a major pharmaceuticals company into the battle against superbug infections in hospitals.

The deal included…

Continue reading

You may also like...